

# Exploring the *xol-1*-independent role of *sex-1* in dosage compensation

Eshna Jash, Dalia Kaufman and Györgyi Csankovszki

Molecular, Cellular and Developmental Biology, University of Michigan – Ann Arbor


## Dosage compensation in *C. elegans*

Transcription from the two X chromosomes is reduced by half to match the gene output from single X in male.


↓XX↓      Xo

## Mechanisms of dosage compensation

There are multiple redundant pathways used by the dosage compensation complex (DCC) to repress and condense the X chromosome




- Condensin I<sup>PC</sup> is a complex that loads onto the hermaphrodite X chromosomes and reduces the expression of genes by half.
- Condensin I<sup>PC</sup> is a powerful experimental model to study the mechanisms of interphase gene regulation by condensin complexes Condensin I and Condensin II.




- The dosage compensation complex (DCC) carries out dosage compensation in *C. elegans*.
- The DCC is comprised of the Condensin I<sup>PC</sup> complex along with proteins such as DPY-21, SDC-1, SDC-2 and SDC-3.

## *sex-1* and its role in dosage compensation




- SEX-1 is a nuclear hormone receptor with a DNA binding domain and an AF-2 domain.
- It directly binds DNA and represses the transcription of genes. The presence of an AF-2 domain suggests that it acts in conjunction with a co-repressor for this function.




- xol-1* is a master regulator of both the male developmental pathway and dosage compensation.
- SEX-1 binds directly to the promoter region of *xol-1* and represses its transcription.

## Does *sex-1* have a downstream role?



- SEX-1 mutations reduce hermaphrodite viability.
- This is not completely rescued by introducing a mutation in *xol-1*.

*sex-1* mutation sensitizes *xol-1* male rescue screen



- xol-1* inhibits the dosage compensation machinery and prevents it from turning on in males.
- In *xol-1* mutant strains, the DCC is turned on inappropriately in males which leads to male-specific lethality.
- Mutations in genes that carry out dosage compensation should rescue these males. This screen is used to detect such genes.
- However, due to multiple redundant pathways in dosage compensation, male rescue cannot always be detected.
- SEX-1 partial loss of function mutant *sex-1* (y263) sensitizes this screen by disrupting dosage compensation through an unknown mechanism.
- Figure: Genes involved in dosage compensation such as *cec-4* aren't able to rescue males on their own. With a *sex-1* mutation in the background, ~7% of the males are rescued (more than *sex-1* or *cec-4* alone).
- This experiment is done in a *xol-1* deletion background, suggesting that *sex-1* has a *xol-1*-independent role in dosage compensation

## Future Directions

- How does *sex-1* perform dosage compensation independent of *xol-1*?
- What is the mechanism of *xol-1*-independent *sex-1*-mediated transcriptional regulation?

## Acknowledgments

Csankovszki Lab

Dr. Györgyi Csankovszki  
Dalia Kaufman  
Dillon Sloan

